VIRGINIA RETIREMENT SYSTEMS ET Al boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 655.3% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 30,060 shares of the biopharmaceutical company’s stock after buying an additional 26,080 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Alnylam Pharmaceuticals were worth $7,417,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ALNY. Bank of Nova Scotia grew its holdings in Alnylam Pharmaceuticals by 0.6% in the 1st quarter. Bank of Nova Scotia now owns 7,798 shares of the biopharmaceutical company’s stock worth $2,580,000 after acquiring an additional 49 shares during the last quarter. SBI Securities Co. Ltd. raised its stake in shares of Alnylam Pharmaceuticals by 27.8% during the third quarter. SBI Securities Co. Ltd. now owns 225 shares of the biopharmaceutical company’s stock valued at $56,000 after acquiring an additional 49 shares during the last quarter. Prestige Wealth Management Group LLC raised its stake in shares of Alnylam Pharmaceuticals by 30.6% during the first quarter. Prestige Wealth Management Group LLC now owns 226 shares of the biopharmaceutical company’s stock valued at $75,000 after acquiring an additional 53 shares during the last quarter. Fortitude Family Office LLC raised its stake in shares of Alnylam Pharmaceuticals by 10.5% during the third quarter. Fortitude Family Office LLC now owns 578 shares of the biopharmaceutical company’s stock valued at $143,000 after acquiring an additional 55 shares during the last quarter. Finally, Glenmede Trust Co. NA grew its stake in shares of Alnylam Pharmaceuticals by 8.3% in the first quarter. Glenmede Trust Co. NA now owns 731 shares of the biopharmaceutical company’s stock worth $242,000 after purchasing an additional 56 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In other Alnylam Pharmaceuticals news, EVP Bryan Supran sold 1,758 shares of the firm’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the sale, the executive vice president directly owned 12,807 shares in the company, valued at $2,905,652.16. This trade represents a 12.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on the company. Barclays reduced their price target on Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating on the stock in a report on Monday, August 3rd. HC Wainwright reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday. Royal Bank Of Canada dropped their price objective on Alnylam Pharmaceuticals from $345.00 to $280.00 and set an “outperform” rating for the company in a report on Friday. Weiss Ratings reiterated a “hold (c)” rating on shares of Alnylam Pharmaceuticals in a research report on Thursday. Finally, BMO Capital Markets reissued an “outperform” rating and set a $290.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $317.95.
View Our Latest Report on ALNY
Key Stories Impacting Alnylam Pharmaceuticals
Here are the key news stories impacting Alnylam Pharmaceuticals this week:
- Positive Sentiment: Quarterly results exceeded expectations. Alnylam reported $16.26 in adjusted earnings per share versus the $1.66 consensus estimate, while revenue rose 16.7% year over year to $1.46 billion, slightly above forecasts. The company maintained its fiscal 2026 product-sales outlook and expects $4.2 billion–$4.5 billion in 2026 TTR sales. Alnylam Q3 earnings beat
- Positive Sentiment: Several analysts still see substantial long-term upside. Chardan Capital, TD Cowen, Goldman Sachs and RBC retained positive ratings, although they reduced their price targets. Their revised targets remain well above the current trading level. Chardan Capital rating
- Neutral Sentiment: Pipeline investment could support future growth but increases execution risk. Alnylam expanded the TRITON-CM nucresiran heart-disease study to approximately 2,250 patients while maintaining an anticipated launch around 2030. Management described its conviction in the program as high, but the longer timeline limits near-term revenue benefits. Alnylam TTR sales and trial update
- Negative Sentiment: Demand-growth concerns overshadowed the earnings beat. Slower Amvuttra patient starts and moderating U.S. Amvuttra and Onpattro sales growth raised concerns that the company’s core TTR business may be losing momentum. Management also acknowledged that it needs to improve execution, adding to uncertainty around the franchise. ALNY demand growth concerns
- Negative Sentiment: Analyst sentiment became more cautious. Bernstein downgraded ALNY to “market perform,” while Stifel cut its rating to “hold.” Multiple firms lowered price targets, including Bernstein from $376 to $199 and Goldman Sachs from $536 to $320, reflecting increased valuation and policy risks.
Alnylam Pharmaceuticals Trading Down 5.2%
NASDAQ:ALNY opened at $165.00 on Friday. The company has a 50-day moving average price of $236.49 and a 200-day moving average price of $286.19. Alnylam Pharmaceuticals, Inc. has a 12 month low of $163.30 and a 12 month high of $479.79. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75. The stock has a market cap of $22.08 billion, a price-to-earnings ratio of 8.57 and a beta of 0.28.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share for the quarter, beating analysts’ consensus estimates of $1.66 by $14.60. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 246.94%. The firm had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. During the same quarter in the previous year, the firm posted $2.90 EPS. The company’s revenue for the quarter was up 16.7% compared to the same quarter last year. Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.58 EPS for the current year.
Alnylam Pharmaceuticals Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.
Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.
Featured Stories
- Five stocks we like better than Alnylam Pharmaceuticals
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
